Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 22nd Century Group, Inc.XXII · Entity 8519 | Director | November 10, 2025 | November 14, 2025 |
| Asterias Biotherapeutics, Inc.AST · Entity 159180 | Director | June 21, 2018 | June 25, 2018 |
| Flyte Aviation, Inc.VTAK · Entity 8648 | Director | March 26, 2026 | March 30, 2026 |
| Insight Molecular Diagnostics Inc.IMDX · Entity 6631 | Director | July 01, 2026 | July 07, 2026 |
| SMITH MICRO SOFTWARE, INC.SMSI · Entity 7775 | Director | March 09, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
22nd Century Group, Inc.
Report date November 10, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,481 |
Reported balance
After 2025-11-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-11-10 · Grant · Acquired 17,295 · Balance 17,481 F1: The restricted stock units vest 1/3 per year on November 10, 2026, 2027 and 2028, subject to continued service with the Company. F2: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-23 stock split effectuated by the issuer on June 20, 2025. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2035-11-10 | Direct | 51,888 |
Reported balance
After 2025-11-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-10 · Grant · Acquired 51,888 · Balance 51,888 F3: Options vest 1/3 per year on the anniversary of the date of grant, subject to continued service with the Company. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $46.23 · Expires 2035-03-10 | Direct | 553 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 553 F3: Options vest 1/3 per year on the anniversary of the date of grant, subject to continued service with the Company. F2: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-23 stock split effectuated by the issuer on June 20, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest 1/3 per year on November 10, 2026, 2027 and 2028, subject to continued service with the Company.
F2: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-23 stock split effectuated by the issuer on June 20, 2025.
F3: Options vest 1/3 per year on the anniversary of the date of grant, subject to continued service with the Company.
Asterias Biotherapeutics, Inc.
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-21 | Direct | 20,000 |
Reported balance
After 2018-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-21 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2026-02-28 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20,000 |
| Series A Common StockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2027-03-29 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2020-03-31 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2019-03-31 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2018-06-21 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 20,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors.
Flyte Aviation, Inc.
Report date March 26, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-03-26 | Direct | 40,000 |
Reported balance
After 2026-03-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-26 · Grant · Acquired 40,000 · Balance 40,000 F1: Options vest 100% on 180 day anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 100% on 180 day anniversary of grant date.
Insight Molecular Diagnostics Inc.
Report date July 01, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 156,785 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Tax withholding · Disposed 12,100 · Balance 156,785 F1: The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 55,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market. |
| Common Stock, no par valueSEC Table I · non-derivative | IndirectSee footnote | 7,804 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,804 F2: These shares of Common Stock are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and, in such capacity, has the right to vote and dispose of securities held by JBA, including the shares of Common Stock reported here. |
| Common Stock, no par valueSEC Table I · non-derivative | IndirectSee footnote | 7,804 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,804 F3: These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and, in such capacity, has the right to vote and dispose of securities held by MJA, including the shares of Common Stock reported here. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 55,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.
F2: These shares of Common Stock are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and, in such capacity, has the right to vote and dispose of securities held by JBA, including the shares of Common Stock reported here.
F3: These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and, in such capacity, has the right to vote and dispose of securities held by MJA, including the shares of Common Stock reported here.
SMITH MICRO SOFTWARE, INC.
Report date March 09, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,007 |
Reported balance
After 2026-03-09 transaction · row 1
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 12,500 · Balance 88,007 F1: Unrestricted stock award granted pursuant to the Company's Amended and Restated Omnibus Equity Incentive Plan. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse IRA | 1,875 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,875 |
| Common StockSEC Table I · non-derivative | IndirectBy MJA Investment | 1,875 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,875 F2: Shares held by MJA Investment, a limited liability company, with respect to which the reporting person makes investment decisions. The reporting person disclaims ownership of these securities, and this report shall not be deemed an admission that the reporting person is beneficial owner of these securities for the purpose of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy JBA Investment | 1,875 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,875 F3: Shares held by JBA Investment, a limited liability company, with respect to which the reporting person makes investment decisions. The reporting person disclaims ownership of these securities, and this report shall not be deemed an admission that the reporting person is beneficial owner of these securities for the purpose of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Unrestricted stock award granted pursuant to the Company's Amended and Restated Omnibus Equity Incentive Plan.
F2: Shares held by MJA Investment, a limited liability company, with respect to which the reporting person makes investment decisions. The reporting person disclaims ownership of these securities, and this report shall not be deemed an admission that the reporting person is beneficial owner of these securities for the purpose of Section 16 or any other purpose.
F3: Shares held by JBA Investment, a limited liability company, with respect to which the reporting person makes investment decisions. The reporting person disclaims ownership of these securities, and this report shall not be deemed an admission that the reporting person is beneficial owner of these securities for the purpose of Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2019 Filed Sep 18, 2019 20:59 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 50,000 | $2.16 | $108,130.00 |
DisclosureSEC source: 0001209191-19-050090 · doc4.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,447 F1 · price: The price of $2.1626 per share represents a weighted average of prices ranging from $2.11 to $2.21 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 00:06 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-042836 · doc4.xml · derivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-07-16 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| February 12, 2019 Filed Feb 15, 2019 00:46 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010442 · doc4.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,610 F1 · security: Restricted Stock Grant - Vesting in 12 equal monthly installments beginning on March 12, 2019 Read SEC document |
| August 30, 2018 Filed Sep 5, 2018 01:33 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-049408 · doc4.xml · derivative · entry 2 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-08-29 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 26, 2018 Filed Aug 1, 2018 01:38 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock purchase warrants · Derivative | 52,447 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001493152-18-010760 · ownership.xml · derivative · entry 2 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,447 Underlying: Common stock · 52,447 shares Expires 2024-02-01 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 26, 2018 Filed Aug 1, 2018 01:38 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock, no par value | 52,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010760 · ownership.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,447 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:36 UTC | Asterias Biotherapeutics, Inc. AST · Entity 159180 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-18-029798 · form4.xml · derivative · entry 2 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The stock options vest equally over the next four quarters, beginning on the June 30, 2018 contingent upon continued service on the Board of Directors. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:28 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | Conversion10% Series B Convertible Preferred Stock · Derivative | 50 | $1,000.00 Strike: $1.14 | $50,000.00 |
DisclosureSEC source: 0001209191-18-031862 · doc4.xml · derivative · entry 2 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The 10% Series B Convertible Preferred Stock is convertible into Smith Micro Software, Inc. common stock at a price per share of $1.14. F2 · derivative.expiration_date: The 10% Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:28 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | ConversionCommon Stock | 43,860 | $1.14 | $50,000.40 |
DisclosureSEC source: 0001209191-18-031862 · doc4.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 18, 2017 21:03 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | GrantCommon Stock | 50,000 | $1.10 | $55,000.00 |
DisclosureSEC source: 0001209191-17-033635 · doc4.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,750 F1 · security: Private placement purchased from the Issuer. Read SEC document |
| May 17, 2018 Filed Jul 21, 2017 21:30 UTC Amendment | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | GrantCommon Stock | 50,000 | $1.10 | $55,000.00 |
DisclosureSEC source: 0001209191-17-046008 · doc4a.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,750 F1 · security: Private placement purchased from the Issuer. F2 · balance_after: Due to a clerical error, the balance that was originally reported did not reflect a 1:4 reverse stock split that took effect on August 17, 2016. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:26 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019717 · doc4.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 F1 · security: Restricted Stock Grant - Vesting in 12 equal monthly installments beginning on April 12, 2018 Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:30 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | Grant10% Series B Convertible Preferred Stock · Derivative | 50 | $1,000.00 Strike: $1.14 | $50,000.00 |
DisclosureSEC source: 0001209191-17-055129 · doc4.xml · derivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 43,860 shares Expires not disclosed F1 · derivative.exercise_price: The 10% Series B Convertible Preferred Stock is convertible into Smith Micro Software, Inc. common stock at a price per share of $1.14. F2 · derivative.expiration_date: The 10% Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| June 15, 2017 Filed Jun 20, 2017 01:09 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040971 · doc4.xml · derivative · entry 2 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. Read SEC document |
| June 15, 2017 Filed Jun 20, 2017 01:09 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 6,520 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040971 · doc4.xml · derivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,520 Underlying: Common Stock · 6,520 shares Expires 2027-06-14 F1 · shares: Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018. F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:09 UTC | Asterias Biotherapeutics, Inc. AST · Entity 159180 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001140361-17-014428 · form4.xml · derivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-29 F1 · security: The stock options vest over four equal quarterly installments beginning on March 31, 2017, contingent upon continued service on the Board of Directors. Read SEC document |
| March 08, 2017 Filed Mar 13, 2017 21:12 UTC | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020231 · doc4.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,750 F1 · security: Restricted Stock Grant - Vesting in 12 equal monthly installments beginning on 04/08/2017 Read SEC document |
| March 08, 2017 Filed Jul 21, 2017 21:30 UTC Amendment | SMITH MICRO SOFTWARE, INC. SMSI · Entity 7775 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046007 · doc4a.xml · nonDerivative · entry 1 Arno Andrew · CIK 0001472122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 F1 · security: Restricted Stock Grant - Vesting in 12 equal monthly installments beginning on 04/08/2017 F2 · balance_after: Due to a clerical error, the balance that was originally reported did not reflect a 1:4 reverse stock split that took effect on August 17, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.